Initial Dosing of Citalopram for Anxiety in Adults
For most adults with anxiety, start citalopram at 20 mg once daily, but reduce to 10 mg daily in patients ≥60 years old, those with hepatic impairment, CYP2C19 poor metabolizers, or those taking CYP2C19 inhibitors—all due to QT prolongation risk. 1
Standard Initial Dosing
The FDA-approved starting dose for citalopram is 20 mg/day for most adults 1. While the original efficacy trials for depression showed that 40-60 mg/day doses were most effective, with 10-20 mg/day showing less clear effects 1, subsequent safety data regarding QT prolongation has fundamentally changed dosing recommendations. Clinical data in anxiety disorders specifically suggests that 10-60 mg/day can be effective, with a mean effective dose around 33 mg/day 2.
Mandatory Dose Reductions to 20 mg Maximum
You must reduce the maximum dose to 20 mg/day (typically starting at 10 mg/day) in the following high-risk groups due to significantly increased drug exposure and QT prolongation risk:
Age ≥60 Years
- Citalopram AUC increases 23-30% and half-life increases 30-50% in older adults 1
- Start 10 mg/day, maximum 20 mg/day
Hepatic Impairment
- Oral clearance reduced by 37% and half-life doubled in hepatic dysfunction 1
- Start 10 mg/day, maximum 20 mg/day
CYP2C19 Poor Metabolizers
- Steady-state Cmax increases 68% and AUC increases 107% 1
- Start 10 mg/day, maximum 20 mg/day
- Recent evidence shows CYP2C19 phenotype effects are amplified in elderly patients, with poor metabolizers showing 2.1-fold higher exposure 3
Concomitant CYP2C19 Inhibitors
- Drugs like omeprazole, esomeprazole, cimetidine, fluconazole, or fluoxetine significantly impair citalopram metabolism 1
- Start 10 mg/day, maximum 20 mg/day
- The DDI risk is substantially greater in older adults than younger adults 4
QT Prolongation Risk Assessment
Before initiating citalopram, screen for:
- Personal or family history of long QT syndrome or sudden cardiac death
- Congenital long QT syndrome
- Concurrent QT-prolonging medications 5
- Electrolyte abnormalities (hypokalemia, hypomagnesemia)
- Cardiac disease or arrhythmia history
Important caveat: While citalopram does prolong QT interval in a dose-dependent manner 5, actual cases of torsades de pointes or sudden cardiac death in patients taking ≤60 mg/day without other risk factors are extremely rare 6. The FDA restrictions are based on pharmacokinetic data rather than clinical outcomes, but adherence is mandatory for medicolegal reasons and patient safety.
Renal Impairment
- Mild-to-moderate renal impairment: No dose adjustment needed (only 17% reduction in clearance) 1
- Severe renal failure (CrCl <20 mL/min): Data insufficient, but caution advised 7
CYP2D6 Status
- No dose adjustment needed for CYP2D6 poor metabolizers—citalopram levels are not significantly affected by CYP2D6 phenotype 1
Management of Persistent Anxiety
If anxiety persists after 2-6 weeks at initial dose:
For standard-risk patients (started at 20 mg/day):
For high-risk patients (maximum 20 mg/day):
Critical Safety Monitoring
- Baseline ECG is prudent in patients with any cardiac risk factors, though not universally required in low-risk patients
- Monitor for serotonin syndrome, especially with concomitant serotonergic drugs 10
- Be aware that even therapeutic doses can rarely cause severe adverse events (SIADH, cardiac toxicity) in susceptible individuals, particularly with drug interactions 11
- Side effects are dose-related and more pronounced at 20 mg than 10 mg initially, which may affect tolerability and adherence 8
Common pitfall: Prescribing >20 mg/day in elderly patients or those with hepatic impairment remains common in practice 12, but this significantly increases risk without additional benefit and constitutes inappropriate prescribing.